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The role of NEFA in eating behaviour is still poorly known. Our objective was to examine whether etomoxir (ETO), an inhibitor of NEFA oxi-
dation, or (2)-hydroxycitrate (HCA), an inhibitor of lipogenesis which may indirectly stimulate NEFA oxidation, alters satiety. Post-lunch satiety
was measured in eight normal-weight male subjects who were deprived of time cues and received on three occasions either ETO (320 mg), HCA
(2 g) or placebo (PLA) in random order. Between lunch and dinner, blood was withdrawn continuously and collected every 10 min for measures of
plasma concentrations of glucose, insulin, lactate, TAG, NEFA, b-hydroxybutyrate (BHB), leptin and ghrelin. Results showed that HCA began to
decrease hunger and desire to eat compared to PLA and ETO 210 min after lunch and increased satiety duration compared to PLA by 70 (SE 23)
min (P,0·05), but did not modify energy intake at dinner. ETO did not affect any variable of satiety. HCA increased NEFA concentrations during
the pre-dinner period, whereas ETO increased and decreased plasma concentrations of NEFA and BHB, respectively. Mean differences in plasma
NEFA concentrations between HCA and PLA were predictive of the differences in satiety duration between treatments (r 2 0·71, P,0·01). Among
treatments, plasma leptin concentration at dinner onset was the only blood variable correlated with energy intake at this meal (r 20·75,
P,0·0005). In healthy, normal-weight men, acute HCA increased the intensity and duration of satiety possibly via increased NEFA disposal
for oxidation.
(2 )-Hydroxycitrate: Eating: Fatty acid oxidation: NEFA: Leptin
Obesity is a major health problem in industrialized countries,
and its prevalence continues to increase(1,2). Diet character-
istics that favour passive overeating may contribute to the
development of obesity. Consumption of dietary fats above
the organism’s ability to oxidize them is a primary suspect
in this context(3). Treatments improving this imbalance
between fat intake and oxidation may therefore hold some
therapeutic potential.
In man, satiety is usually assessed by recording: (1) its
intensity through subjective feelings; (2) its duration through
the delay until the next meal request occurs, i.e. the inter-
meal interval (IMI); and (3) the amount eaten in a meal pre-
sented at a fixed or freely chosen time. Simultaneous assess-
ment of all three parameters can be considered to be the
most accurate evaluation of satiety in man.
A large body of evidence suggests that metabolic factors
contribute to satiety. Thus, a drop in circulating glucose has
been repeatedly reported to be associated with meal
initiation(4). Furthermore, fatty acid oxidation inhibitors such
as methyl-palmoxirate(5) and mercaptoacetate(6) have been
shown to stimulate eating, and in rats mercaptoacetate stimu-
lated eating by shortening IMI duration without altering meal
size(6), suggesting that oxidation of NEFA contributes to sati-
ety. Consistent with this concept, an impaired NEFA oxidation
was shown to be a predictive factor of diet-induced obesity in
animals(7) and man(8). Furthermore, the eating-stimulatory
effect of mercaptoacetate was found to be mediated by
abdominal vagal afferents(9), consistent with the idea that a
metabolic hunger signal may originate from the liver.
Studies addressing the role of fat metabolism in man mainly
used etomoxir (ETO) and (2 )-hydroxycitrate (HCA). ETO
reduces NEFA oxidation by inhibiting carnitine-palmytoyl-
transferase-1, the rate-limiting enzyme for the transfer of
long-chain fatty acids across the mitochondrial membrane.
Conversely, HCA, derived from the Indian fruit Garcinia
cambogia, reduces de novo lipogenesis by inhibiting the cyto-
solic enzyme ATP-citrate-lyase(10). By limiting the availability
of malonyl-CoA, ATP-citrate-lyase inhibition might indirectly
increase NEFA oxidation(11). Very few studies, however,
specifically addressed the effects of these agents on satiety.
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When given to normal-weight subjects before a high-fat
breakfast, ETO (150 mg) enhanced hunger feelings and
increased energy intake(12). For its part, under various experi-
mental conditions, and in different populations, HCA did not
affect satiety in all but one study(13).
Therefore, we here specifically examined whether ETO or
HCA affect satiety in man and alter metabolism in a way
that is consistent with their presumed metabolic mechanisms
of action. To do so, we modelled a spontaneous IMI according
to a previously described method(14) and continuously recorded
eating behaviour and various blood parameters related to fat
metabolism or food intake, including the hormones ghrelin
and leptin.
Experimental methods
Subjects
Male subjects (20–30 years old) were recruited through adver-
tisements posted at ETH Zurich. Smokers, trained athletes and
subjects who had food allergies or aversions to the foods pro-
vided during the experiment were excluded. Other exclusion
criteria were any personal or family history of diabetes or
other metabolic disease, use of medication or a change in
body weight .1 kg during the previous year. Moreover, we
included only subjects who were not restrained or disinhibited
and who did not experience strong hunger feelings between
meals. To verify this criterion, subjects completed the FEV
questionnaire, the German version of the Three Factor
Eating Questionnaire(15) with cut-off scores of 9 and 7 for
restrained eating and disinhibition, respectively. Another
criterion was to never or very rarely (less than two times
per week) eat something between lunch and dinner, and to
eat a diet with $35 % of energy derived from fat. These
two conditions were considered necessary because modulators
of fat metabolism do not appear to affect eating at low levels
of dietary fat(12) and because fatty acids appear to contribute
to satiety only in case of long IMI(16). To verify these two
criteria, a 5 d food diary and a FFQ were completed by the
subjects and were analysed with the EBISpro software
(Dr J. Erhardt, University of Hohenheim, 2002). Twelve sub-
jects were initially selected, but one decided on short notice
not to participate and another one was excluded because
he experienced a severe vagal malaise when the intravenous
catheter was introduced on the first day. Two other subjects
completed only two of the three conditions and were therefore
excluded from final analyses. Characteristics of the remaining
eight subjects who completed all three treatments and whose
data were analysed are shown in Table 1. Fat mass was esti-
mated by bioelectrical impedance analysis using a body fat
scale (BF 555; Tanita Corp., Tokyo, Japan) after an overnight
fast and with the bladder voided. Subjects gave their written
informed consent and were financially compensated for com-
pleting the study. The procedure was approved by the Ethics
Committee of the Swiss Federal Institute of Technology
Zurich (ETH Zurich).
Study design
A single-blind within-subject design was used, with each sub-
ject participating on three test days for placebo (PLA), ETO
and HCA separated by 1 week. In each subject we determined:
(1) the temporal pattern of hunger ratings from lunch until the
spontaneous dinner request, (2) the time between the end of
lunch and the dinner request, (3) the amount of food eaten
during the ad libitum dinner, and (4) the temporal pattern of
the plasma glucose, NEFA, b-hydroxybutyrate (BHB), lactate,
TAG, insulin, leptin and ghrelin concentrations from 30 min
before lunch to the dinner request.
Pharmacological agents
Timing of administration and doses of agents were chosen
according to their kinetic profiles, their optimal bioavailability
and the doses used in previous studies. Thus, the ETO dose
was in the range of doses showing an effect on fatty acid
oxidation and hunger in previous studies. For example,
hunger and RQ were increased 200 min after only a single
150 mg dose in Kahler et al. (12). An ETO dose of 600 mg
given over 36 h has also been shown to increase RQ in healthy
subjects(17), whereas 100 mg given daily decreased fatty acid
oxidation in subjects with type 2 diabetes(18). For HCA, we
chose the highest dose that was provided in 12 h in previous
studies, i.e. 2 g(19 – 21). Although the bioavailability of oral
HCA is low, the plasma concentration achieved in human
subjects after oral administration of 2 g HCA has been found
to be higher than after the administration of an HCA dose in
rats that had clear effects on fat metabolism (0·022 mmol/kg
v. 0·017 mmol/kg)(22,23). Subjects received ETO (Dr. Horst
P.O. Wolf GmbH, Allensbach, Germany), HCA (CitrinR
500; Power Health Products Ltd, York, UK) or PLA at three
time-points, i.e. just before breakfast, 10 min before and
240 min after lunch. The ETO treatment consisted of PLA
before breakfast and 160 mg ETO before and after lunch
(320 mg ETO in total). The HCA treatment consisted of
500 mg HCA before breakfast and 750 mg HCA before and
after lunch (2 g in total). In the PLA condition, placebo was
given on all three occasions. Substances were taken with a
glass of water, facing the experimenter.
Foods
For breakfast, a choice of food items based on those
usually consumed by the subjects for breakfast was provided.
Table 1. Subject characteristics (n 8)
(mean values with their standard errors)
Mean SE
Age (years) 22·9 2·4
Height (m) 1·84 0·05
Weight (kg) 78·8 7·1
BMI (kg/m2) 23·2 3·3
Fat mass (kg) 10·4 3·3
Fat mass (%) 13·0 3·3
F1 (cognitive restraint) 4·7 3·0
F2 (desinhibition) 3·8 3·3
F3 (hunger) 4·9 2·5
Mean daily energy intake (MJ) 13·7 2·0
Mean fat intake (%) 46 2
F1–F3, factors 1–3 of the FEV questionnaire, German version of the Three Factor
Eating Questionnaire(15).
B. Gatta et al.1868
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114508143604
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 20:09:05, subject to the Cambridge Core terms of use, available at
The amount was free in the first session. This breakfast was
identical in the two further sessions.
Based on our previous studies showing that manipulations
mainly affect consumption of the first item of a meal,
especially if this is the main dish(24), lunch and dinner com-
prised only two items each. Lunch consisted of lasagna bolog-
naise (5·1 kJ/g, 17 % protein, 37 % fat, 46 % carbohydrate, 1 kg
served at the first session) and chocolate cake ‘black forest’
(5·8 kJ/g, 14 % protein, 39 % fat, 47 % carbohydrate, 350 g
served at the first session). As for breakfast, lunch was
consumed ad libitum in the first session, and the energy
intake was then determined and fixed for the subsequent
sessions. Dinner consisted of rice, chicken and curry
(4·8 kJ/g, 20 % protein, 35 % fat, 45 % carbohydrate, 900 g
served) and chocolate-flavoured dessert cream (5·4 kJ/g,
12 % protein, 18 % fat, 70 % carbohydrate, 500 g served).
All dinner items were served in large dishes. All food items
served at lunch and dinner were rated highly palatable by
each subject in a prior test using hedonic scales. Water was
provided ad libitum, but water consumption was not measured.
No other beverage was served or allowed.
Subjective ratings of satiety
Motivation to eat was assessed using 100 mm visual analogue
scales for hunger, desire to eat and gastric fullness, each
anchored with ‘not at all’ and ‘extremely’ at the left and
right ends, respectively. The scales were rated every 30 min
from before lunch until after dinner, but some ratings were
randomly interspersed to prevent them from providing any
time cue to the subjects.
Blood sampling and plasma assays
Blood samples were obtained as previously described, with a
specially designed double-lumen catheter (MTB Medizintech-
nik, Amstetten, Germany)(25). Briefly, this system fits into an
18-gauge indwelling cannula inserted into an antecubital
vein, and blood is continuously withdrawn throughout the
session, at a flow rate of 300ml/min via a peristaltic pump.
Blood is heparinized (7 IU/ml) without any back-infusion of
heparin into the vein. The dilution is accounted for when cal-
culating final concentration of the variables. Blood samples
were collected automatically in a machine programmed to
change tubes every 10 min. It takes about 10 min for the
blood to flow from the vein to the sample tube. This lag
time is accounted for in the data analysis. Blood samples
were immediately centrifuged (3400 g, 15 min, 88C), and the
plasma was aliquoted into Eppendorf tubes and stored at
2808C for further analyses.
Glucose, lactate, NEFA, TAG and BHB were determined
by standard colorimetric and enzymatic methods adapted
for the Cobas Mira autoanalyser (Hoffman la Roche, Basel,
Switzerland). Insulin was determined by RIA using the
SB-INSI-5 kit (CEA, Gif-sur-Yvette, France; 7 % accuracy)
with a sensitivity of 2mU/ml. Plasma total ghrelin and leptin
were determined by RIA using the commercial Sensitive
Human Leptin kit and the Human Ghrelin kit (Linco Research,
St Charles, MO, USA). Mean intra- and inter-assay CV were
3·5 and 5·3 % for leptin and 5·9 and 10·3 % for ghrelin.
Procedure
Figure 1 shows the daily schedule for each subject. Three sub-
jects were studied on each day. They were asked to arrive at
the laboratory at 08.00 hours after an overnight fast. They
were then served a breakfast of items corresponding to their
usual breakfast as indicated by the 5 d food diary. At 11.00
hours, subjects were confined to individual quiet rooms with-
out windows. They were seated in comfortable armchairs and
deprived of time cues by exposing them to artificial light, and
by removing all potential sources of visual and auditory time
references such as watches, computers or radios. Between
12.30 and 13.00 hours, but for each subject at the same time
for all conditions, a catheter was inserted into an antecubital
vein for blood sampling. Lunch was served 30 min after the
onset of blood sampling. Meal duration was not fixed but
measured. Subjects were instructed to spontaneously ask for
dinner as soon as they felt hungry and certainly not to delay
their request in order to not bother experimenters. When
a subject requested dinner, he was asked to guess the current
time. The catheter was then withdrawn and the subject was
served dinner. A microwave oven was used to quickly heat
the main dish of the dinner and to serve it only minutes
after the request. Before and after consumption, food plates
were accurately and covertly weighed to determine actual
intakes. Independent of the time of dinner requests, subjects
were not allowed to leave the laboratory before 22.00 hours,
to avoid any premature dinner request.
Statistical analysis
Unless otherwise indicated, all results are presented as means
and standard errors of the eight subjects who completed all
Fig. 1. Schedule of experimental proceedings for a subject. Breakfast (B) was based on items usually consumed by the subjects. Amount eaten was free in the
first session, but was identical in the two subsequent sessions. Continuous blood collection began between 12.30 and 13.00 hours across subjects, but exactly at
the same time across treatments. Lunch (L) was served 30 min after the catheter was inserted. Treatment (T; placebo, etomoxir or hydroxycitrate) was taken at
8.00, 11.00 and 16.30 hours. Visual analog scales for hunger, desire to eat and gastric fullness were rated every 30 min with some ratings randomly interspersed
to obscure any time cues. The dinner had to be freely requested by subjects (Dfr). Dt, deprivation of time cues.
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three treatments. Statistical analyses were performed using
Systat software version 10.2 (SPSS Inc., Chicago, IL, USA).
The biological parameters were subjected to a stepwise
analysis for serial measurements according to the recommen-
dation of Matthews et al. (26). Thus, for each blood parameter,
four variables of interest were determined: (1) a post-lunch
profile from the start of lunch to the time the first dinner
was requested across all subjects and all conditions, i.e. the
minimum time prior to any dinner request, which occurred
at 260 min; (2) a pre-dinner profile starting 60 min prior to
dinner request; (3) an area under the curve (AUC) calculated
by the trapezoidal method for the time from lunch onset to the
first dinner request of each subject separately across all con-
ditions; (4) a mean plasma concentration over the whole
IMI. The first variable allowed the kinetics of the plasma par-
ameters to be studied during a fixed time period including all
subjects and conditions. The second variable focused on the
important period preceding a meal, where major metabolic
changes may occur. In subjects who requested their dinner
less than 320 min after lunch in a session (four from twenty-
four), the post-lunch and the pre-dinner profiles shortly over-
lapped. The third variable estimated the maximum difference
that could be calculated taking into account all three con-
ditions for each subject. The fourth variable provided one
value of the concentrations of each parameter during the
whole IMI.
Satiety scores were analysed using the same method as for
the first and second (post-lunch profile and AUC) variables of
the plasma parameters.
Post-lunch and pre-dinner profiles were analysed by two-
way ANOVA for repeated measures with conditions and
time as within-subject factors. The level of significance was
fixed at P,0·05. For significant interactions between con-
ditions and time, subsequent comparisons of means were ana-
lysed by Scheffe’s contrasts. AUC and mean concentrations
were compared between conditions by Student’s t test adjusted
for multiple comparisons by the Holm’s procedure(27).
Relationships between plasma parameters and behavioural
data were calculated using Pearson correlations. Predictive
equations were fitted by multivariate linear regressions using
a backward stepping procedure with a level of 0·1 required
for a factor to be included. Predictive equations were modelled
for three behavioural variables: (1) the difference of IMI dura-
tion between treatments (ETO, HCA and PLA), (2) total
energy intake at dinner and (3) energy derived from the first
item of the dinner meal. For the first variable, tested predictive
factors were mean plasma concentrations of each plasma
parameter and treatments, whereas for the second and third
variables the predictive factors tested were plasma concen-
trations at dinner request and treatments.
Results
Consistent with the assumption that the time-blinding was
effective, there was a significant difference between the real
and the guessed clock time for all three treatments (22·5
(SE 10·6), 55·7 (SE 33·5) and 80·7 (SE 22·9) min for PLA,
ETO and HCA, respectively, all P,0·05). Subjects reported
no side-effects during any session.
Satiety
Mean energy intake at the free-choice breakfast as determined
in the first session was 3877 (SE 393) kJ and mean proportions
of macronutrients consumed were 12 (SE 1) % protein, 25
(SE 2) % fat and 63 (SE 1) % carbohydrate. Mean energy
intake at the two-item lunch was 4505 (SE 178) kJ and con-
sisted of 14, 38 and 47 % protein, fat and carbohydrate,
respectively. At dinner, energy intake was not significantly
different between treatments (Fig. 2(A)). The time between
the end of lunch and the dinner request was longer after
HCA than after PLA (þ73 (SE 23) min, P,0·05) but not
between PLA and ETO (Fig. 2(B)). Mean hedonic scores for
lunch items were high and not different between treatments
(79 (SE 3), 79 (SE 3) and 81 (SE 4) mm for PLA, ETO and
HCA, respectively).
Prior to lunch, hunger and gastric fullness scores were not
different among treatments (Fig. 3). Post-lunch hunger profiles
until 240 min showed an interaction between time and treat-
ment (P¼0·01), with hunger scores at 210 and 240 min
being lower with HCA than with PLA and ETO treatments
(all P,0·05). A treatment effect was found for post-lunch
Fig. 2. Energy intake at dinner (A) and mean delay between lunch and spon-
taneous dinner request (B) after placebo (PLA), etomoxir (ETO) or hydroxyci-
trate (HCA). Values are means with their standard errors depicted by vertical
bars. a,b Mean values with unlike superscript letters were significantly differ-
ent (P,0·05).
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desire to eat profile until 240 min (P,0·05) and the interaction
between time and treatment approached significance
(P¼0·07). Comparisons showed that at 210 and 240 min,
desire to eat scores were lower with HCA than with ETO
(both P,0·05). No treatment effect was found for post-
lunch gastric fullness profiles.
Hunger and desire to eat AUC were smaller with HCA than
with PLA and ETO treatments (all P,0·05). Gastric fullness
AUC was larger with HCA than with PLA treatment
(P,0·05), but the difference failed to reach significance
with ETO.
Plasma parameters
Figs. 4 and 5 show post-lunch and pre-dinner profiles of all
plasma parameters. After lunch, treatment only affected
Fig. 3. Time course (left panel) and area under the curve (AUC, right panel) of hunger (A), desire to eat (B) and gastric fullness scores (C) on visual analogue
scales between lunch and 240 min, i.e. the delay of the first dinner request across subjects and across conditions (X, placebo (PLA); A, etomoxir (ETO); K, hydro-
xycitrate (HCA)). Values are means with their standard errors depicted by vertical bars. a,b Mean values with unlike superscript letters were significantly different
(P,0·05).
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plasma NEFA (P,0·05), without a treatment £ time inter-
action. Post-lunch plasma NEFA concentrations were higher
with ETO than with HCA (P,0·05), but the difference
failed to reach significance between ETO and PLA (P¼0·07).
In the pre-dinner period, treatment affected plasma lactate
(P,0·05), NEFA (P,0·05) and BHB (P,0·005) profiles
without an interaction with time. With HCA treatment, pre-
dinner concentrations of plasma lactate were lower than
with PLA (P,0·05) and ETO (P,0·05), whereas NEFA
concentrations were higher than with PLA (P,0·05). The
difference in the pre-dinner profile of NEFA between HCA
and ETO treatments just failed to reach significance
(P¼0·07). The pre-dinner concentrations of BHB were
lower with ETO than with PLA (P,0·05) and HCA treat-
ments (P,0·01).
Fig. 4. Postprandial (left panel) and pre-dinner (right panel) plasma glucose
(A), insulin (B), lactate (C) and ghrelin (D) concentrations during the interval
between lunch and spontaneously requested dinner ( ) (X, placebo (PLA);
A, etomoxir (ETO); K, hydroxycitrate (HCA)). Values are means with their
standard errors depicted by vertical bars. HCA mean values were signifi-
cantly different from those of PLA and ETO: *P,0·05.
Fig. 5. Postprandial (left panel) and pre-dinner (right panel) plasma TAG (A),
NEFA (B), b-hydroxybutyrate (BHB; C) and leptin (D) concentrations during
the interval between lunch and spontaneously requested dinner ( ) (X,
placebo (PLA); A, etomoxir (ETO); K, hydroxycitrate (HCA)). Values are
means with their standard errors depicted by vertical bars. HCA mean values
were significantly different from those of ETO, *P,0·05. HCA mean
values were significantly different from those of PLA, #P,0·05. ETO mean
values were significantly different from those of HCA and PLA, †P,0·05.
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AUC and mean IMI concentrations are shown in Table 2.
ETO increased the AUC for plasma NEFA compared to
PLA (P,0·01) or HCA treatment (P,0·005) and reduced
the AUC for BHB compared to PLA (P,0·05). Mean
plasma NEFA concentrations were higher with HCA and
ETO treatment than with PLA (P,0·05 and P,0·01, respect-
ively), and mean BHB concentrations were lower with ETO
than with PLA and HCA treatments (both P,0·05).
Correlations between satiety and plasma parameters
Among plasma parameters, the difference in mean NEFA con-
centrations between HCA and PLA treatments was the only
one correlated with treatment differences in IMI duration
(r 0·84, P,0·01). The difference in mean plasma NEFA
concentrations was also the only predictive factor for the
difference in IMI duration between HCA and PLA (r 2 0·71,
P,0·01) (Table 3).
When all treatments were pooled, plasma leptin concen-
tration at dinner request was highly correlated with energy
intake at dinner (r 20·75, P,0·0005). When treatments
were analysed separately, the correlation was significant
with HCA (r 20·79, P,0·05) and ETO treatments (r 20·91,
P,0·005), but failed to reach significance with PLA (r 20·63,
P¼0·07). Furthermore, a correlation between plasma glucose
concentrations and energy intake at dinner was found
(r 20·55, P¼0·005). Both leptin and glucose were only corre-
lated with intake of the first meal item (r 20·75, P,0·0005
for leptin; r 20·67, P,0·0005 for glucose) and not with des-
sert. The best fitting model for predicting energy intake at
dinner from plasma parameters at meal request only included
leptin with a negative coefficient (r 2 0·56, P,0·00005)
(Table 3). When only the first item of the dinner was
considered, the best fitting model included leptin, ghrelin
and lactate, the latter two with a positive coefficient (r 2 0·67,
P,0·00005).
Discussion
The aim of the present study was to investigate the role of
NEFA in satiety by administering to young and healthy
male subjects two modulators of NEFA metabolism, ETO
and HCA, which were expected to decrease and increase sati-
ety, respectively. The present results confirmed only the latter
prediction, i.e. HCA increased the subjective post-lunch sati-
ety scores and the mean duration of satiety until the dinner
request in our group of subjects by more than 70 min, although
energy intake at dinner was unaffected. This increased delay is
unlikely to be caused by nausea or other digestive malaise.
Because of the continuous blood withdrawal, we regularly
asked subjects if they experienced any abnormal sensation
or manifestation, but they reported none. The fact that their
energy intake at dinner was not different among HCA, PLA
and ETO conditions also argues for the absence of any diges-
tive malaise.
The satiety-enhancing effect of HCA did not appear to be
mediated by a change in food palatability because no differ-
ences in hedonic scores were found. This is consistent with
findings in rats, in which HCA did not induce a conditioned
taste aversion to saccharin(28). The fact that the length of
Table 2. Area under the curve (AUC) and plasma concentrations of hormones and metabolites*
(Mean values with their standard errors)
PLA ETO HCA
Mean SE Mean SE Mean SE
Glucose
AUC (mmol/l £ min) 1577 113 1592 110 1599 98
Plasma (mmol/l) 4·63 0·09 4·69 0·12 4·67 0·12
Insulin
AUC (mU/ml £ min) 7133 851 7347 922 7826 1099
Plasma (mU/ml) 18·38 2·08 20·07 2·79 18·64 2·33
Lactate
AUC (mmol/l £ min) 430 23 440 29 428 25
Plasma (mmol/l) 1·27 0·03 1·34 0·04 1·23 0·05
Ghrelin
AUC (ng/ml £ min) 327 48 331 38 338 49
Plasma (ng/ml) 1·11 0·13 1·11 0·12 1·11 0·11
TAG
AUC (mmol/l £ min) 326 33 371 38 333 52
Plasma (mmol/l) 0·97 0·06 1·17 0·10 0·97 0·09
NEFA
AUC (mmol/l £ min) 86a 11 104b 13 80a 10
Plasma (mmol/l) 0·26a 0·02 0·35b 0·03 0·31b 0·04
BHB
AUC (mmol/l £ min) 11 774a 1964 7609b 1077 9330ab 1112
Plasma (mmol/l) 37·36a 4·51 22·13b 2·24 37·23a 3·34
Leptin
AUC (ng/ml £ min) 1289 515 1342 614 1341 519
Plasma (ng/ml) 3·24 1·20 3·72 1·57 3·72 1·36
BHB, b-hydroxybutyrate; ETO, etomoxir; HCA, (2 )-hydroxycitrate; PLA, placebo.
a,b Mean values within a row with unlike superscript letters were significantly different (P,0·05).
* For details of subjects and procedures, see Experimental methods.
Fatty acid metabolism and satiety in man 1873
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114508143604
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 20:09:05, subject to the Cambridge Core terms of use, available at
satiety was sensitive to HCA and that subjects could not guess
the real time at debriefing argues for the effectiveness of the
time blinding. Thus, in young male subjects in energy equili-
brium and on a naturalistic diet pattern, acute HCA adminis-
tration was effective in prolonging satiety. In previous
studies under varying conditions, we and others have repeat-
edly found that when meals can be freely requested, subjects
adapt to experimental conditions primarily by varying the
IMI rather than meal size(29 – 32). This is in agreement with
results obtained in rats(33). Moreover, the conceptual basis of
the present study was the putative role of NEFA as an
additional source of energy for the metabolic flux during the
IMI, thus prolonging satiety and delaying hunger(30). Meal
onset presumably results from the interaction of metabolic,
neuroendocrine and sensory factors. This of course limits the
relevance of the present results for everyday life, where
times of meals are often fixed by environmental factors.
The observed changes in plasma parameters did not provide
a clear explanation for the effect of HCA on satiety. The
increases in circulating NEFA and BHB (approaching signifi-
cance) during the pre-dinner period are consistent with an
increase in NEFA oxidation by HCA, possibly through an
increased release of NEFA from adipose tissue and their sub-
sequent oxidation. However, substrate oxidation was not
directly measured, which would be necessary to confirm
such an assumption. Some recent data in fact suggest an
enhancing effect of HCA on lipolysis in human adipocytes(34),
but the existence of such an effect in naturalistic conditions
in vivo needs to be demonstrated. On the other hand, plasma
BHB and NEFA concentrations suggest that ETO inhibited
NEFA oxidation, but did not stimulate eating, showing that
an inhibition of NEFA oxidation does not always translate
into a stimulation of eating, providing a contrasted picture
of the relation between NEFA oxidation and satiety.
A crude interpretation of the present results would be that
with HCA a longer period with low glucose and high fat util-
ization is tolerated before eating is initiated. HCA has been
reported to decrease cumulative energy intake in animal
studies, mainly in conditions of enhanced fat synthesis, such
as in animals fed a high carbohydrate diet(35,36), or while re-
feeding after fasting and body weight loss(37 – 40). In man,
HCA doses (1·5–3 g) similar to the one we used were tested
under a variety of conditions (subjects with overweight or
obesity, in positive energy balance, or with normal weight)
and were reported to cause greater weight reduction than con-
trol treatments in many(19,20,41) but not all(42) of these studies.
However, effects of HCA on eating behaviour or subjective
parameters of satiety(13,41 – 44) were scarcely reported, and
none of these studies was specifically designed to examine
the effects of HCA on satiety in normal-weight subjects
eating their regular diet, as in the present experiment. Interest-
ingly, in the only study conducted in weight-stable obese sub-
jects, a reduction in spontaneous intake was found during an
acute experimental session(13).
One possible mechanism of the satiating effect of HCA is
an indirect stimulation of fatty acid oxidation, in particular
in the liver. Hepatic fatty acid oxidation has been proposed
to trigger a vagally mediated satiety signal(6). However, we
have previously shown that subdiaphragmatical vagal deaffer-
entation, a surgical procedure that eliminates all vagal affer-
ents, did not prevent HCA from reducing food intake in
rats(39), suggesting that other mechanisms are involved.
HCA has also been shown to promote whole-body fat oxi-
dation and to spare glucose utilization in mice(45), although
this could not be demonstrated in man(43,44,46,47), except in
conditions of forced de novo lipogenesis such as prolonged
passive overfeeding with a high-carbohydrate diet(48), or
during endurance exercise(49 – 51). While we did not measure
whole-body substrate oxidation in the present study, there
was some evidence of an indirect stimulation of hepatic
NEFA oxidation by HCA. Thus, BHB tracked circulating
NEFA and tended to be higher, and lactate was lower after
HCA than after PLA throughout the pre-dinner period. This
suggests that after HCA administration subjects requested
dinner in a metabolic state characterized by a higher rate of
NEFA oxidation and lower rate of glycolysis according to
the glucose–fatty acid cycle(52). However, an alternative
explanation is that this metabolic profile only reflects the
longer duration of satiety after HCA, with plasma concen-
trations and oxidation of NEFA increasing substantially in
the late part of long IMI(14,16,29,30).
The main limitation of the present study is the absence of
direct measurement of substrate oxidation. It is quite delicate
to assess spontaneous IMI when it is regularly interrupted by
gas-exchange measurements and a respiratory chamber would
be required to examine if, in the present condition, HCA actu-
ally increased whole-body NEFA oxidation. All interpret-
ations concerning fat oxidation are therefore primarily based
on plasma BHB and NEFA concentrations and must be
taken with caution until substrate oxidation during the IMI
is assessed.
We did not observe an effect of HCA on plasma leptin con-
centrations between lunch and dinner. The reported findings in
man of a decrease in circulating leptin or adipose tissue leptin
expression in response to HCA presumably reflect an indirect
effect related to a decrease in fat mass by HCA rather than a
direct effect on leptin production(19 – 21). As we have shown,
even small variations in fat mass can be associated with a sus-
tained decrease in circulating leptin(53). In the present study,
Table 3. Regression models for behavioural variables*
Dependent variable b SE P
DIMI (HCA2PLA)
Constant 242·23 15·51 0·03
NEFA (mmol/l) 675·30 176·869 ,0·01
EIdinner
Constant 5754·21 192·55 ,0·0001
Leptin (ng/ml) 2178·78 33·52 ,0·0005
EIitem1
Constant 459·65 230·98 0·06
Leptin (ng/ml) 235·34 6·59 ,0·0001
Ghrelin (pg/ml) 0·14 0·06 ,0·05
Lactate (mmol/l) 345·56 156·04 ,0·05
b, standard regression coefficient; HCA, (2 )-hydroxycitrate; IMI, inter-meal interval;
PLA, placebo.
* Tested behavioural variables were the difference in IMI between HCA and PLA
conditions (DIMI), total energy intake at dinner (Eidinner) and energy intake
derived from the main dish of the dinner meal presented as first item (EIitem1).
Predictive variables were plasma glucose, insulin, lactate, ghrelin, TAG, NEFA,
b-hydroxybutyrate and leptin concentrations (mean concentrations and concen-
trations at dinner onset for DIMI and energy intake, respectively), and treatments
(PLA, etomoxir, HCA). These equations were the best fitting model for each
dependent variable. The r 2 and significance of each equation are indicated in
the Results. P significant at ,0·1.
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leptin was again a potent negative predictor of energy intake
in the spontaneous requested meal. We repeatedly reported
this relation when subjects were allowed to decide on the
timing of meals and on the amount they ate(14,16). That this
relation is strongest when the first and main item of the
meal is considered is also a constant finding in our studies.
Interestingly, when the first meal item was used for the mod-
elling, ghrelin became also a significant predictor of intake
with a positive coefficient. To our knowledge, a possible
effect of HCA on ghrelin had not been explored yet. Ghrelin
has been implicated in meal initiation in man because its
administration increases food intake(54) and because its
plasma concentration increases before fixed(55) or spon-
taneously requested(56) meals. Here, ghrelin increased before
dinner request to similar concentrations with all treatments.
HCA might also affect satiety by reducing the rate of post-
prandial intestinal glucose absorption(57). This would prolong
glucose delivery from the intestine and, hence, delay a glucopae-
nia-related meal initiation signal. However, no differences in
postprandial blood glucose appearance were found in the present
study, although the frequent blood sampling was appropriate to
observe small kinetic differences. Also, postprandial peaks of
circulating glucose were reached at approximately 45 min
after lunch with all treatments, which corresponds to our
previous findings with this blood-sampling method(58).
Finally, HCA has been shown to reduce serotonin reuptake
in brain, thus increasing serotonin availability and action(59),
to up-regulate genes encoding serotonin receptors(60) and to
substantially increase circulating serotonin concentrations(20).
Although all these effects were demonstrated with a new
HCA extract (SX), an increase in serotoninergic neurotrans-
mission could be a common property of this compound
family, but the present results do not allow us to judge on a
possible contribution of serotonin to the observed HCA
effects.
Contrary to a previous study conducted in young male sub-
jects(12), we failed to show an effect of ETO on eating, and the
metabolic effect of ETO was weaker. In the previous study,
however, ETO increased food intake only in subjects who
were accustomed to high dietary fat intake and when ETO
was given before breakfast after consumption of a 65·8 %
(energy) fat dinner on the previous evening. When ETO was
given after a 60 % fat lunch, it did not increase subsequent
intake, which is similar to the present findings. The macronu-
trient composition of meals in the present study was chosen to
explore the relevance of the role of NEFA and fat metabolism
in everyday life rather than extreme dietary conditions. ETO
supposedly stimulates eating by inhibiting hepatic NEFA oxi-
dation. This mechanism seems not effective or at least of
minor importance under normal eating conditions in man.
Although chosen with caution, according to previous studies
reporting significant effects of ETO and HCA on eating beha-
viour, and considering the kinetics of these two agents, we do
not know whether these doses and modalities of adminis-
tration were optimal. This applies in particular to ETO for
which we did not find an effect.
In conclusion, the present results show for the first time that
HCA can enhance the intensity of satiety sensation and delay
the spontaneous request of the subsequent meal in normal-
weight human subjects during a spontaneous eating pattern.
The mechanism of this effect is still uncertain, but could be
somehow related to an increased availability of NEFA for
the intermeal metabolism.
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